“Chronic thromboembolic pulmonary hypertension in Saudi Arabia: preliminary results from the SAUDIPH registry”. Abdullah M. Aldalaan, Sarfraz A. Saleemi, Ihab Weheba, Abeer Abdelsayed, Pekka Hämmäinen, Maha M. Aleid, Fatima Alzubi, Hamdeia Zaytoun and Nadeen Alharbi. ERJ Open Res 2019; 6: 00218-2019.

This article was originally published with an error in the “Treatment and follow-up” subsection of the results:

“In terms of pharmacological treatment, at the last follow-up visit, 7.9% of patients were on single pulmonary hypertension-specific treatment (mostly macitentan or sildenafil) and 20.6% were on combination pulmonary hypertension-specific treatment (mostly macitentan plus sildenafil) (table 3).”

has now been corrected to:

“In terms of pharmacological treatment, at the last follow-up visit, 29.7% of patients were on single pulmonary hypertension-specific treatment (mostly macitentan or sildenafil) and 20.6% were on combination pulmonary hypertension-specific treatment (mostly macitentan plus sildenafil) (table 3).”

in the article itself.

• Copyright ©ERS 2020